Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2007, Article ID 32403, 5 pages
Clinical Study

The Levels of Ghrelin, TNF-α, and IL-6 in Children with Cyanotic and Acyanotic Congenital Heart Disease

1Division of Pediatric Cardiology, Department of Pediatrics, School of Medicine, Firat University, Elazığ 23119, Turkey
2Department of Biochemistry, School of Medicine, Firat University, Elazığ 23119, Turkey
3Division of Pediatric Endocrinology, Department of Pediatrics, School of Medicine, Firat University, Elazığ 23119, Turkey
4Department of Pediatrics, School of Medicine, Firat University, Elazığ 23119, Turkey

Received 16 March 2007; Accepted 6 July 2007

Copyright © 2007 Erdal Yilmaz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Arvat, L. Di Vito, and F. Broglio et al., “Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans,” Journal of Endocrinological Investigation, vol. 23, no. 8, pp. 493–495, 2000.
  2. R. Peino, R. Baldelli, and J. Rodriguez-Garcia et al., “Ghrelin-induced growth hormone secretion in humans,” European Journal of Endocrinology, vol. 143, no. 6, pp. 11–14, 2000. View at Publisher · View at Google Scholar
  3. A. M. Wren, C. J. Small, and C. R. Abbott et al., “Ghrelin causes hyperphagia and obesity in rats,” Diabetes, vol. 50, no. 11, pp. 2540–2547, 2001. View at Publisher · View at Google Scholar
  4. M. Tschöp, C. Weyer, P. A. Tataranni, V. Devanarayan, E. Ravussin, and M. L. Heiman, “Circulating ghrelin levels are decreased in human obesity,” Diabetes, vol. 50, no. 4, pp. 707–709, 2001.
  5. M. Tschöp, D. L. Smiley, and M. L. Heiman, “Ghrelin induces adiposity in rodents,” Nature, vol. 407, no. 6806, pp. 908–913, 2000. View at Publisher · View at Google Scholar · View at PubMed
  6. M. Kojima, H. Hosoda, and K. Kangawa, “Ghrelin, a novel growth-hormone-releasing and appetite-stimulating peptide from stomach,” Best Practice and Research in Clinical Endocrinology and Metabolism, vol. 18, no. 4, pp. 517–530, 2004. View at Publisher · View at Google Scholar · View at PubMed
  7. M. Nakazato, N. Murakami, and Y. Date et al., “A role for ghrelin in the central regulation of feeding,” Nature, vol. 409, no. 6817, pp. 194–198, 2001. View at Publisher · View at Google Scholar · View at PubMed
  8. H. S. Park, K.-U. Lee, Y. S. Kim, and C. Y. Park, “Relationships between fasting plasma ghrelin levels and metabolic parameters in children and adolescents,” Metabolism Clinical and Experimental, vol. 54, no. 7, pp. 925–929, 2005. View at Publisher · View at Google Scholar · View at PubMed
  9. A. J. Whatmore, C. M. Hall, J. Jones, M. Westwood, and P. E. Clayton, “Ghrelin concentrations in healthy children and adolescents,” Clinical Endocrinology, vol. 59, no. 5, pp. 649–654, 2003. View at Publisher · View at Google Scholar
  10. B. Beutler and A. Cerami, “Cachectin (tumor necrosis factor): a macrophage hormone governing cellular metabolism and inflammatory response,” Endocrine Reviews, vol. 9, no. 1, pp. 57–66, 1988.
  11. K. J. Tracey and A. Cerami, “Tumor necrosis factor: a pleiotropic cytokine and therapeutic target,” Annual Review of Medicine, vol. 45, pp. 491–503, 1994. View at Publisher · View at Google Scholar · View at PubMed
  12. J. Le and J. Vilcek, “Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response,” Laboratory Investigation, vol. 61, no. 6, pp. 588–602, 1989.
  13. A. Abad-Sinden and J. L. Sutphen, “Growth and nutrition,” in Moss and Adams' Heart Disease in Infants, Children, and Adolescents, D. H. Allan, H. P. Gutgesell, E. B. Clark, and D. J. Driscoll, Eds., pp. 325–332, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2001.
  14. M. Gilger, C. Jensen, B. Kessler, P. Nanjundiah, and W. J. Klish, “Nutrition, growth, and gastrointestinal system: basic knowledge for pediatric cardiologist,” in The Science and Practice of Pediatric Cardiology, A. Garson, J. T. Bricker, and P. G. McNamara, Eds., pp. 2354–2370, Lea & Febiger, Philadelphia, Pa, USA, 1990.
  15. R. Unger, M. DeKleermaeker, S. S. Gidding, and K. K. Christoffel, “Calories count. Improved weight gain with dietary intervention in congenital heart disease,” American Journal of Diseases of Children, vol. 146, no. 9, pp. 1078–1084, 1992.
  16. B. Varan, K. Tokel, and G. Yilmaz, “Malnutrition and growth failure in cyanotic and acyanotic congenital heart disease with and without pulmonary hypertension,” Archives of Disease in Childhood, vol. 81, no. 1, pp. 49–52, 1999.
  17. R. L. Gingell and M. G. Hornung, “Growth problems associated with congenital heart disease in infancy,” in Textbook of Gastroenterology and Nutrition in Infancy, E. Lebenthal, Ed., pp. 639–649, Raven Press, New York, NY, USA, 1989.
  18. L. Soriano-Guillén, V. Barrios, and J. Argente, “Physiopathological features and diagnostic utility of ghrelin protein in pediatrics,” Anales de Pediatria, vol. 61, no. 1, pp. 5–7, 2004.
  19. A. M. Haqq, I. S. Farooqi, and S. O'Rahilly et al., “Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome,” The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 1, pp. 174–178, 2003. View at Publisher · View at Google Scholar
  20. D. Baum, R. Q. Beck, and W. L. Haskell, “Growth and tissue abnormalities in young people with cyanotic congenital heart disease receiving systemic-pulmonary artery shunts,” The American Journal of Cardiology, vol. 52, no. 3, pp. 349–352, 1983. View at Publisher · View at Google Scholar
  21. D. Bernstein, J. R. Jasper, R. G. Rosenfeld, and R. L. Hintz, “Decreased serum insulin-like growth factor-I associated with growth failure in newborn lambs with experimental cyanotic heart disease,” Journal of Clinical Investigation, vol. 89, no. 4, pp. 1128–1132, 1992.
  22. R. G. Weintraub, S. Menahem, and G. Werther, “Serum insulin-like growth factor I levels in patients congenital heart disease,” Australian Paediatric Journal, vol. 25, pp. 324–325, 1989.
  23. A. Inui, “Cancer anorexia-cachexia syndrome: are neuropeptides the key?,” Cancer Research, vol. 59, no. 18, pp. 4493–4501, 1999.
  24. D. P. Kotler, “Cachexia,” Annals of Internal Medicine, vol. 133, no. 8, pp. 622–634, 2000.
  25. L. M. Freeman and R. Roubenoff, “The nutrition implications of cardiac cachexia,” Nutrition Reviews, vol. 52, no. 10, pp. 340–347, 1994.
  26. W. L. Morrison and R. H. T. Edwards, “Cardiac cachexia,” British Medical Journal, vol. 302, no. 6772, pp. 301–302, 1991.
  27. A. Rosenthal, “Nutritional conciderations in the prognosis treatment of children with congenital heart disease,” in Textbook of Pediatric Nutrition, R. M. Suskind and L. Levinter-Suskind, Eds., pp. 383–391, Raven Press, New York, NY, USA, 1993.
  28. J. McMurray, I. Abdullah, H. J. Dargie, and D. Shapiro, “Increased concentrations of tumour necrosis factor in ‘cachectic’ patients with severe chronic heart failure,” British Heart Journal, vol. 66, no. 5, pp. 356–358, 1991.
  29. N. Nagaya, M. Uematsu, and M. Kojima et al., “Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors,” Circulation, vol. 104, no. 17, pp. 2034–2038, 2001.